IDEAYA Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $3.11B
- P/E (TTM)
- –
- Dividend yield
- –
About IDEAYA Biosciences
Pharmaceutical Preparations, SIC 2834
IDEAYA Biosciences, Inc. is a precision medicine oncology company that discovers and develops targeted therapeutics for cancer patients. The company focuses on developing synthetic lethality therapies and antibody-drug conjugates directed at molecularly defined solid tumors. Its clinical pipeline includes darovasertib, a protein kinase C inhibitor evaluated for the treatment of uveal melanoma, as well as investigational programs targeting the MTAP pathway and DNA damage response mechanisms. IDEAYA evaluates its drug candidates as monotherapies and in rational combinations for patients with specific genetic alterations, while collaborating with pharmaceutical partners to advance clinical development.
The company conducts clinical development activities primarily in the United States and collaborates globally with international pharmaceutical organizations. Its principal executive offices and headquarters are located in South San Francisco, California, and it maintains additional leased facilities in San Diego, California.
Summary of the business section of IDEAYA Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- IDEAYA Biosciences, Inc.
- Founded
- 2015
- Headquarters
- South San Francisco, CA
- Address
- 5000 Shoreline Ct, Suite 300 94080
- Phone
- (650) 443-6209
- Website
- ideayabio.com
- Employees
- 145, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- PricewaterhouseCoopers LLP, San Jose, California
Stock & identifiers
- Ticker
- IDYA
- Exchange
- Nasdaq
- IPO date
- May 24, 2019
- Shares outstanding
- 96M, Jul 31, 2026
- Public float
- $1.80B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1676725
- CUSIP
- 45166A102
- ISIN
- US45166A1025
- LEI
- 549300ULW08F62IJML11
- EIN
- 47-4268251
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Yujiro S. Hata | President and CEO, Director | 690,695 |
| Briseno Andres Ruiz | Chief Accounting Officer | 36,016 |
| Theodora Ross | Chief Development Officer | – |
| Joshua Bleharski | Chief Financial Officer | – |
| Michael Anthony White | Chief Scientific Officer | 0 |
| Darrin Beaupre | Chief Medical Officer | – |
| Douglas B. Snyder | SVP, General Counsel | 2,080 |
| Stuart Dorman | Chief Commercial Officer | – |
| Wendy L. Yarno | Director | – |
| Catherine J. Mackey | Director | – |
| Scott W. Morrison | Director | – |
| Malcolm Garret Hampton | Director | – |
| Terry J. Rosen | Director | 16,346 |
| Jeffrey Stein | Director | 57,644 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Yujiro S. Hata | $9.51M | $15.70M | $2.72M | $247 | $125 |
| FY2024 Yujiro S. Hata | $16.93M | $5.81M | $4.54M | $184 | $93 |
| FY2023 Yujiro S. Hata | $6.00M | $15.72M | $2.02M | $254 | $94 |
| FY2022 Yujiro S. Hata | $3.33M | $1.79M | $2.01M | $130 | $90 |
| FY2021 Yujiro S. Hata | $3.85M | $7.28M | $2.47M | $169 | $100 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had a total of 145 employees.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 24, 2019 | IPO | Initial public offering priced (424B4 prospectus) |
| May 17, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |